CIGB-247: A VEGF-based therapeutic vaccine that reduces experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c mouse tumors

Vaccine

Volumn 30, Issue 10, 2012, Pages 1790-1799

  Bequet Romero, Mónica ^a   Morera, Yanelys ^a   Ayala ávila, Marta ^a   Ancizar, Julio ^a   Soria, Yordanka ^a   Blanco, Aracelys ^a   Suárez Alba, Jesús ^a   Gavilondo, Jorge V ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

Angiogenesis; Cancer; CIGB 247; Immunotherapy; Metastasis; Vaccine; VEGF

Indexed keywords

CANCER VACCINE; CIGB 247; IMMUNOGLOBULIN G; RECOMBINANT VASCULOTROPIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CELL DENSITY; CELL PROLIFERATION; CELLULAR IMMUNITY; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DELAYED HYPERSENSITIVITY; FEMALE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IN VITRO STUDY; LUNG CARCINOMA; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNITY, HUMORAL; IMMUNOTHERAPY, ACTIVE; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84857457850     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.01.006     Document Type: Article

References (47)

1. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363(July (5)):411-422.
2. Biotechnology medicines in development. Pharmaceuticals Research and Manufacturers of America (PhRMA) Report 2011. ; 2011. http://www.phrma.org/.
3. Vergati M., Intrivici C., Huen N.Y., Schlom J., Tsang K.Y. Strategies for cancer vaccine development. J Biomed Biotechnol 2010, 201. pii: 596432 [Epub 2010 July 11].
4. Rao B., Han M., Wang L., Gao X., Huang J., Huang M., et al. Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review. J Transl Med 2011, 9(January (1)):17.
5. Cavallo F., Forni G. Recent advances in cancer immunotherapy with an emphasis on vaccines. Expert Rev Vaccines 2009, 8(January (1)):25-28.
6. Cheever M.A., Allison J.P., Ferris A.S., Finn O.J., Hastings B.M., Hecht T.T., et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009, 15(September (17)):5323-5337.
7. Croix B.S. Vaccines targeting tumor vasculature: a new approach for cancer immunotherapy. Cytotherapy 2007, 9(1):1-3.
8. St C.B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., et al. Genes expressed in human tumor endothelium. Science 2000, 289(August (5482)):1197-1202.
9. Folkman J. Angiogenesis: an organizing principle for drug discovery?. Nat Rev Drug Discov 2007, 6(April (4)):273-286.
10. Okaji Y., Tsuno N.H., Saito S., Yoneyama S., Tanaka M., Nagawa H., et al. Vaccines targeting tumour angiogenesis--a novel strategy for cancer immunotherapy. Eur J Surg Oncol 2006, 32(May (4)):363-370.
11. Wei Y.Q. Immunotherapy of tumors with vaccines based on xenogeneic homologous molecules. Anticancer Drugs 2002, 13(March (3)):229-235.
12. Eichholz A., Merchant S., Gaya A.M. Anti-angiogenesis therapies: their potential in cancer management. Onco Targets Ther 2010, 3(June):69-82.
13. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005, 69(Suppl. 3):11-16.
14. Smirne C., Camandona M., Rosso E., Bellone G., Emanuelli G. Vascular endothelial growth factor. From basic research to clinical application. Minerva Med 1999, 90(January (1-2)):15-23.
15. Ziogas A.C., Gavalas N.G., Tsiatas M., Tsitsilonis O., Politi E., Terpos E., et al. VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2. Int J Cancer 2011, (March):10.
16. Gabrilovich D.I., Ishida T., Nadaf S., Ohm J.E., Carbone D.P. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999, 5(October (10)):2963-2970.
17. Morera Y., Bequet-Romero M., Ayala M., Lamdan H., Agger E.M., Andersen P., et al. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants. Angiogenesis 2008, 11(4):381-393.
18. Morera Y., Bequet-Romero M., Ayala M., Velazco J.C., Perez P.P., Alba J.S., et al. Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates. Vaccine 2010, 28(April (19)):3453-3461.
19. Fernandez A., Mesa C., Marigo I., Dolcetti L., Clavell M., Oliver L., et al. Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. J Immunol 2011, 186(January (1)):264-274.
20. de León J., Fernandez A., Clavell M., Labrada M., Bebelagua Y., Mesa C., et al. Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25- effector and naturally occurring CD4+CD25+ regulatory T cells function. Int Immunol 2008, 20(April (4)):591-600.
21. Mesa C., de L.J., Rigley K., Fernandez L.E. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for dendritic cell activation. Vaccine 2006, 24(April (Suppl. 2)). S2-42-3.
22. de León J., Fernandez A., Mesa C., Clavel M., Fernandez L.E. Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother 2006, 55(April (4)):443-450.
23. Mesa C., de L.J., Rigley K., Fernandez L.E. Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation. Vaccine 2004, 22(August (23-24)):3045-3052.
24. Morera Y, Bequet-Romero M, Ayala M, Puente P, Castro J, Sánchez J, et al. Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates, doi:10.1016/j.vaccine.2011.10.082; 2011. doi:10.1016/j.vaccine.2011.10.082.
25. Eisenbach L., Hollander N., Greenfeld L., Yakor H., Segal S., Feldman M. The differential expression of H-2K versus H-2D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells. Int J Cancer 1984, 34(October (4)):567-573.
26. Gabri M.R., Menna P.L., Scursoni A.M., Gomez D.E., Alonso D.F. Role of tumor-derived granulocyte-macrophage colony-stimulating factor in micebear ing a highly invasive and metastatic mammary carcinoma. Pathobiology 1999, 67(4):180-185.
27. Morera Y., Lamdan H., Bequet M., Ayala M., Rojas G., Munoz Y., et al. Biologically active vascular endothelial growth factor as a bacterial recombinant glutathione S-transferase fusion protein. Biotechnol Appl Biochem 2006, 44(April (Pt 1)):45-53.
28. Weiss L., Ward P.M. Lymphogenous and hematogenous metastasis of Lewis lung carcinoma in the mouse. Int J Cancer 1987, 40(October (4)):570-574.
29. Godoy-Ramirez K., Makitalo B., Thorstensson R., Sandstrom E., Biberfeld G., Gaines H. A novel assay for assessment of HIV-specific cytotoxicity by multiparameter flow cytometry. Cytometry A 2005, 68(December (2)):71-80.
30. Wang X.Q., Duan X.M., Liu L.H., Fang Y.Q., Tan Y. Carboxyfluorescein diacetate succinimidyl ester fluorescent dye for cell labeling. Acta Biochim Biophys Sin (Shanghai) 2005, 37(June (6)):379-385.
31. Fuentes D., Avellanet J., Garcia A., Iglesias N., Gabri M.R., Alonso D.F., et al. Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model. Breast Cancer Res Treat 2010, 120(April (2)):379-389.
32. Langley R.R., Fidler I.J. The seed and soil hypothesis revisited-The role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 2011, 128(June (11)):2527-2535.
33. Steeg P.S., Anderson R.L., Bar-Eli M., Chambers A.F., Eccles S.A., Hunter K., et al. Preclinical drug development must consider the impact on metastasis. Clin Cancer Res 2009, 15(July (14)):4529-4530.
34. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15(March (3)):232-239.
35. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15(March (3)):220-231.
36. Ebos J.M., Kerbel R.S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011, 8(March (4)):210-221.
37. Bagri A., Berry L., Gunter B., Singh M., Kasman I., Damico L.A., et al. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin Cancer Res 2010, 16(August (15)):3887-3900.
38. Wei Y.Q., Huang M.J., Yang L., Zhao X., Tian L., Lu Y., et al. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci U S A 2001, 98(September (20)):11545-11550.
39. Jiang C., Xiong W., Lu B.Y., Gonda M.A., Chang J.Y. Synthesis and immune response of non-native isomers of vascular endothelial growth factor. Biochemistry 2010, 49(August (31)):6550-6556.
40. Kamstock D., Elmslie R., Thamm D., Dow S. Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol Immunother 2007, 56(August (8)):1299-1309.
41. Rad F.H., Le B.H., Paturance S., Larcier P., Genne P., Ryffel B., et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci U S A 2007, 104(February (8)):2837-2842.
42. Chambers A.F., MacDonald I.C., Schmidt E.E., Koop S., Morris V.L., Khokha R., et al. Steps in tumor metastasis: new concepts from intravital videomicroscopy. Cancer Metastasis Rev 1995, 14(December (4)):279-301.
43. Alonso D.F., Skilton G., Farias E.F., Bal de Kier J.E., Gomez D.E. Antimetastatic effect of desmopressin in a mouse mammary tumor model. Breast Cancer Res Treat 1999, 57(October (3)):271-275.
44. Alonso D.F., Farias E.F., Ladeda V., Davel L., Puricelli L., Bal de Kier J.E. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. Breast Cancer Res Treat 1996, 40(3):209-223.
45. Chen X., Oppenheim J.J., Howard O.M. BALB/c mice have more CD4+CD25+T regulatory cells and show greater susceptibility to suppression of their CD4+CD25- responder T cells than C57BL/6 mice. J Leukoc Biol 2005, 78(July (1)):114-121.
46. Shojaei F., Wu X., Malik A.K., Zhong C., Baldwin M.E., Schanz S., et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007, 25(August (8)):911-920.
47. Fidler I.J. The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 2011, 21(April (2)):107-112.